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Topical treatment with CYP26 inhibitor 
talarozole (R115866) dose dependently alters 
the expression of retinoid-regulated genes  
in normal human epidermis
In this randomized phase I trial Pavez Loriè et al. studied the effects 
of topical talarozole, a retinoic acid metabolism blocking agent, 
on retinoid biomarkers in normal skin. Gels containing talarozole 
(0.35% or 0.07%) and vehicle were applied once daily for 9 days 
on either buttock of 16 healthy volunteers. Epidermal shave biopsies 
(for mRNA analysis) and punch biopsies were taken. The following 
genes were studied by quantitative real-time PCR: cellular retinoic 
acid binding protein 2 (CRABP2), cytokeratins (KRT2 and KRT4), 
CYP26A1, CYP26B1, CYP26C1 and CYP2S1, two enzymes in the 
retinol metabolism (RALDH2 and LRAT) and two proinflammatory 
cytokines (IL-1a and TNF-a). Talarozole dose-dependently increased 
the mRNA expression of CRABP2, KRT4, CYP26A1 and CYP26B1, 
and decreased the expression of KRT2 and IL-1a compared with 
vehicle-treated skin. No mRNA change in retinol-metabolizing 
enzymes was seen. There was no induction of epidermal thickness 
or overt skin inflammation. Talarozole influences the biomarker pat-
tern mostly in consistency with increased retinoic acid stimulation, 
but has low irritancy potential. Br J Dermatol 2009; 160:26–36.
Psoralen plus ultraviolet A ± interferon-a treatment 
resistance in mycosis fungoides: the role of tumour 
microenvironment, nuclear transcription factor-κB 
and T-cell receptor pathways
Wozniak et al. studied the prognostic factors enabling prediction of 
resistance of patients with MF to PUVA ± IFN-a treatment. The gene 
expression profiling of pretreatment samples from 29 patients diag-
nosed as having MF stage IA, IB or IIA, enrolled in a randomized 
PUVA vs. PUVA + IFN-a clinical trial, was analysed using cDNA 
microarrays. A Cox model (SAM) and gene set enrichment analy-
sis were used for identification of genes and biologically significant 
pathways related to resistance to treatment. Genes involved in NF-jB 
signalling, TCR signalling, cytokine signalling and proliferation were 
differentially expressed between responders and nonresponders. 
Interestingly, expression of markers representative of those pathways 
was found not only in the tumour cells, but also in specific subpop-
ulations of macrophages, dendritic cells and other non-neoplastic 
cell types constituting the tumour microenvironment, likely to be 
involved in the promotion of survival and proliferation of cutane-
ous T-cell lymphoma. Gene expression changes in both the tumour 
and the tumour microenvironment are an important determinant 
of treatment outcome in patients with early-stage MF. Some proin-
flammatory factors such as NF-jB, inflammatory cytokines and their 
receptors in addition to TCR-associated molecules could be promis-
ing targets for MF treatment. Br J Dermatol 2009; 160:92–102.
Frontal fibrosing alopecia:  
clinical presentations and prognosis
Tan and Messenger studied the case notes of 18 women (aged 34–71 
years) diagnosed with frontal fibrosing alopecia from 1993 to 2008 
to determine the clinical features and natural history of this condi-
tion. Three patients were premenopausal. All had scarring fronto-
temporal recession. This was associated with partial or complete 
loss of eyebrows in 15 patients and four had hair loss at other sites. 
One had keratosis pilaris-like papules on the face. Three patients had 
oral lichen planus, of whom two also had cutaneous lichen planus 
affecting other sites of the body. Treatments given included intral-
esional triamcinolone acetonide, 0.1% tacrolimus ointment and oral 
hydroxychloroquine. Progression of frontotemporal recession was 
seen in some patients, but not all. In one patient the hair line receded 
by 30 mm over 72 months, whereas in another patient there was no 
positional change in the hair line after 15 years. Frontal fibrosing alo-
pecia is more common in postmenopausal women, but it can occur 
in younger women. It may be associated with mucocutaneous lichen 
planus. Recession of the hair line may progress inexorably over many 
years but this is not inevitable. It is not clear whether treatment alters 
the natural history of the disease. Br J Dermatol 2009; 160:75–9.
Patch test dose–response study: polysensitized 
individuals do not express lower elicitation 
thresholds than single/double-sensitized individuals
Carlsen et al. studied elicitation dose–response curves and elicita-
tion thresholds in 13 polysensitized vs. 38 single ⁄ double-sensitized 
patients to nickel sulphate, methyldibromo glutaronitrile (MDBGN) 
and p-phenylenediamine (PPD). The ratio between the doses elicit-
ing a response in 50% of patients in the two groups was used as 
a measure for relative sensitivity. The dose–response curves in the 
polysensitized group were shifted to the right for MDBGN and PPD, 
and shifted to the left for nickel sulphate, compared with the single ⁄ 
double-sensitized group. The relative sensitivity for each of the three 
allergens and a combined relative sensitivity for all three allergens 
were not significantly different when comparing the polysensitized 
and single⁄double-sensitized groups. No increased sensitivity, in 
the form of distinct elicitation thresholds, could be demonstrated in 
polysensitized individuals compared with individuals with one or 
two contact allergies. Br J Dermatol 2009; 160:103–6.
Biologic therapies for psoriasis: practical 
experience in a U.K. tertiary referral centre
A retrospective case-note review was undertaken to identify 
patients initiated on biologic therapies for severe psoriasis in a U.K. 
centre. The efficacy and safety of efalizumab, etanercept and inflix-
imab were documented. At 12 weeks the efficacy of efalizumab 
(n = 28), etanercept (n = 70) and infliximab (n = 20), as assessed 
by PASI 75 (75% decrease from baseline score), was 24%, 35% 
and 85%, respectively. All biologics used were well tolerated. 
Combination therapy with systemic agents was required either at 
transition to, or to counter relapse while established on, a biologic 
therapy in 30% of cases. Streamlined approaches to screening and 
funding significantly (P ≤ 0.05) hastened the initiation of biologics. 
In a cohort of U.K. patients with severe psoriasis biologic thera-
pies have proved to be a significant step forward in expanding the 
therapeutic armamentarium for psoriasis. Pharmacovigilance, in 
the form of registries, is essential to assess the long-term safety of 
such drugs. Br J Dermatol 2009; 160:162–9.
